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For nearly a century, the fruit fly, Drosophila melanogaster, has proven to be a valuable
tool in our understanding of fundamental biological processes, and has empowered
our discoveries, particularly in the field of neuroscience. In recent years, Drosophila
has emerged as a model organism for human neurodegenerative and neuromuscular
disorders. In this review, we highlight a number of recent studies that utilized the
Drosophila model to study repeat-expansion associated diseases (READs), such as
polyglutamine diseases, fragile X-associated tremor/ataxia syndrome (FXTAS), myotonic
dystrophy type 1 (DM1) and type 2 (DM2), and C9ORF72-associated amyotrophic lateral
sclerosis/frontotemporal dementia (C9-ALS/FTD). Discoveries regarding the possible
mechanisms of RNA toxicity will be focused here. These studies demonstrate Drosophila
as an excellent in vivo model system that can reveal novel mechanistic insights into
human disorders, providing the foundation for translational research and therapeutic
development.
Keywords: polyglutamine disease, Huntington’s disease, C9orf72, amyotrophic lateral sclerosis (ALS),
frontotemporal dementia (FTD), myotonic dystrophy, fragile X, spinocerebellar ataxia
INTRODUCTION
For nearly two decades, the fruit fly Drosophila melanogaster has been utilized as a model
organism to study a number of human neurodegenerative and neuromuscular diseases (Chan
and Bonini, 2000; Muqit and Feany, 2002; Zoghbi and Botas, 2002; Sang and Jackson, 2005;
Marsh and Thompson, 2006; Yu and Bonini, 2011; Jaiswal et al., 2012; McGurk et al., 2015).
The fruit fly offers multiple advantages for the investigation of the molecular mechanisms of
diseases. Having short life cycle, high offspring numbers, low costs for maintenance, simple yet
powerful genetic manipulations, the availability of mutants, and other genetic tools are only some
of the many attractive features of Drosophila as a model system. Drosophila was introduced into
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scientific research over a 100 years ago, and quickly became an
invaluable tool that empowers our discoveries and understanding
of a wide range of biological processes, such as embryogenesis,
neural development, synaptic plasticity, and even complex
behaviors such as decision-making and learning and memory
(Bellen et al., 2010; Spindler and Hartenstein, 2010; Harris and
Littleton, 2015). Sequencing of the Drosophila and the human
genomes revealed remarkably high similarities between the fly
and humans (Adams et al., 2000; Rubin, 2000), with ∼75% of
the genes implicated in human genetic disorders having at least
one homolog in Drosophila (Rubin, 2000; Reiter et al., 2001).
Most importantly, despite the obvious anatomic divergence
between the fly and humans, the fundamental aspects of cell
biology are highly conserved, including the regulation of gene
expression, synaptogenesis, cell proliferation, cell differentiation,
cell signaling, and cell death. Many genes and pathways
that are being studied in mammals were originally identified
in Drosophila. For instance, the mammalian Wnt gene was
originally identified as wingless in Drosophila with its mutation
resulting in flies having no wings (Sharma and Chopra, 1976).
Wnt/wingless is now widely known for its involvement in a
broad variety of conserved cellular processes and human diseases
(Korkut and Budnik, 2009).
THE ADVANTAGES OF USING
DROSOPHILA FOR STUDYING HUMAN
DISEASE-ASSOCIATED GENES
Comparing with mammals, Drosophila has much simpler
genetics. The fruit fly has only four pairs of homologous
chromosomes, as compared to 20 in mice and 23 in humans.
Flies also have a much simpler nervous system, with ∼200,000
neurons in the fly brain comparing to ∼100 billion neurons
in humans. Despite its simplicity, the fly nervous system is
comprehensive, allowing the fly to perform a wide variety of
behaviors, such as feeding, walking, climbing, courtship, and
communication. Fruit flies are even capable of being trained
with fear/reward conditioning paradigms to examine complex
biological processes like learning and memory. These features
of Drosophila make it an ideal organism for modeling complex
disorders because it can be used to model a specific subset
of phenotypes associated with a particular disease, which will
simplify the analysis.
A wide range of genetic manipulation techniques have
been developed in Drosophila which are impractical to be
implemented in mammals. For instance, the availability of
P-elements mutants in libraries is certainly an advantage that is
exclusive to the Drosophila community. Originally, P-elements
are stretches of transposable DNA consisting of inverted repeats
surrounding a transposase gene to allow hopping of the mobile
element on chromosomes (Rubin and Spradling, 1982; O’Hare
and Rubin, 1983). Drosophila researchers exploited its mobility,
and designed P-elements without the transposase but with
reporter genes. By pairing up this modified P-element with
an inducible transposase, the P-element can then be randomly
inserted into the genome to disrupt the transcription of
downstream genes. With this technique, libraries of “P-element
mutants” for tenths of thousands of genes are constructed
(Cooley et al., 1988; Bier et al., 1989; Spradling et al., 1999;
Bellen et al., 2004). Researchers can now conveniently access the
information of these mutants from FlyBase (http://flybase.org),
and order them from resource centers such as the Bloomington
Drosophila Stock Center. In addition, due to the nature that
the mobilization of the P-elements are typically imprecise,
these fly lines provide a means to generate excision mutants
(Hummel and Klämbt, 2008). Lastly, the introduction of flipase
recombination targets into P-elements have provided the option
of generating precise chromosomal deletions between two P-
elements (Hummel and Klämbt, 2008). The development of these
genetic tools have greatly enhanced the process of genome editing
in Drosophila.
Another popular technique used in Drosophila research is
the GAL4/UAS binary transgene overexpression system, which
is perhaps one of the most versatile expression system ever
developed in Drosophila (Brand and Perrimon, 1993). GAL4 is a
yeast transcription factor that drives the expression of a transgene
downstream of an Upstream Activation Sequence (UAS). Usually,
a GAL4 fly line expresses GAL4 under the control of a cell- or
tissue-specific promoter. This can be achieved by enhancer-trap
screens, or the fusion of identified promoters with the GAL4 gene
and subsequently microinjecting the constructs into fly embryos
to produce specific GAL4 driver lines (Duffy, 2002). For the
operon, a human disease gene of interest is usually subcloned
into an expression construct containing UAS, which is then
also microinjected into fly embryos to produce transgenic fly
lines. The UAS operon lines will be crossed to GAL4 fly lines,
resulting in the overexpression of the human disease gene of
interest in the desired cells/tissues (Duffy, 2002). If the expression
of pathological human genes in the fly successfully yields an
abnormal phenotype, such as degeneration in the photoreceptor
neurons of the fly eye, genetic screens, and pharmacological
screens can then be performed to search for genetic modifiers
and small molecules that may impact the etiology of the
corresponding human disorders.
One of the most prominent aspects of the fly model is its
capacity to conduct genetic screens to identify novel molecular
components of pathological pathways. Mice models of human
diseases are absolutely vital to advancing our understanding of
the diseases, but nevertheless with limitations. In Drosophila,
the classical forward genetic screens can be performed using
mutagens such as ethyl methane sulfonate to generate mutants
(St Johnston, 2002; Yamamoto et al., 2014). Since this approach
is unbiased, it allows the identification of novel genes from the
entire genome, which would otherwise be extremely difficult to
perform in mouse models. Due to having a short life cycle, the
simplicity of having only four pairs of homologous chromosomes
and the availability of balancer chromosomes for the suppression
of recombination, the isolation of mutations from Drosophila is
much easier than that from a mouse. Apart from forward genetic
screens, tools for high throughput reverse genetic screens are
also available. Genetic tools for RNAi-mediated knockdown are
easily accessible from stock centers such as the ViennaDrosophila
Resource Center and Harvard Transgenic RNAi Project, making
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it possible to conveniently perform reverse genetic screens in the
fly model (Dietzl et al., 2007).
External features of Drosophila makes it suitable for
performing large scale screens of genes and pharmacologicals.
Bristles, wing veins and the compound eye are all external
structures of the organism that can be affected by genetic or
cellular changes, and can easily be observed and scored under
a stereomicroscope (Yamamoto et al., 2014). The compound
eye is mostly composed of photoreceptor neurons, and is
commonly used as a model to monitor neurodegeneration,
allowing the identification of novel genetic modifiers and drugs
in screens (St Johnston, 2002). Using the GAL4/UAS system,
toxic RNAs or toxic proteins that commonly occurs in human
neurodegenerative and neuromuscular diseases can be expressed
in the fly eye, which often results in a rough-eye phenotype.
Since the eye is not required for viability, this allows effective
screening of genes or pharmacologicals that can alleviate or
enhance the degeneration.Most compounds can be simplymixed
into standard Drosophila food to be consumed by larvae and
adult flies. Alternatively, compounds can be injected into adult
flies as well if a high, acute dosage is needed in the adult
stage. The identification of novel genetic modifiers or drugs may
reveal the physiological role of disease-related genes and promote
our understanding of the disease pathology (Zoghbi and Botas,
2002; Hirth, 2010; Pandey and Nichols, 2011; McGurk et al.,
2015). Thus, Drosophila serves as an important platform for the
discoveries of new components of pathological pathways and the
development of pioneer therapeutic approaches.
THE LIMITATIONS OF MODELING HUMAN
DISEASES IN THE FRUIT FLY
Although the use of classical genetic screens of Drosophila
provides an unbiased approach to gain insights into human
degenerative diseases, fly mutations may not be precise
representations of human disease mutations. This is because the
classical fly mutants from forward genetic screens are typically
loss-of-function alleles. Yet in human diseases, mutations can
have complex presentations, including both loss-of-function of
the wild type allele and gain-of-function of the mutant allele.
Most of the times, this gain-of-function effect can still bemodeled
in Drosophila by overexpressing the mutant protein using the
GAL4/UAS system (St Johnston, 2002). But for some diseases
which the loss-of-function of the wild type protein plays a major
role in the disease etiology, if there are noDrosophila orthologs of
the corresponding human disease-associated genes, then perhaps
the fly is not a suitable model for the particular disease.
Furthermore, while the GAL4/UAS system is an extremely
effective and versatile system, it is after all an overexpression
system that may give rise to the typical caveats of overexpression
studies. The magnitude of overexpression in a model
can be tremendously different from the clinical situation
(Floresco et al., 2005). Sometimes, even overexpressing a
wild type version of a gene may cause a disease phenotype
(Prelich, 2012). In fact, excess GAL4 protein in the
Drosophila eye may lead to degeneration (Kramer and
Staveley, 2003). Hence, it is paramount for Drosophila
researchers to set up appropriate controls to ensure that
the phenotypes observed are not simply overexpression
artifacts.
Lastly, it is a concern of whether the fly models can
faithfully recapitulate the selective neuronal death and associated
phenotypes of human neurological disorders. Although the
Drosophila photoreceptor degeneration provides a convenient
readout, it mostly reflects generic neurotoxicity instead of
selective neurotoxicity that is disease-specific. Thus, it is
important to verify relevant phenotypes using other systems that
are more specific to the particular types of disease. For instance,
for myotonic dystrophy, it is crucial to verify any degeneration
phenotype in a neuromuscular system, like the Drosophila or
mouse neuromuscular junction (de Haro et al., 2006; Panaite
et al., 2013).
Despite all the limitations, Drosophila has so far proven
to be a valid and useful tool in unraveling the etiology of
human diseases and identifying compounds that can improve
symptoms and modify the course of human diseases. Success
examples include the rescuing of disease-like phenotypes in fly
models of fragile X syndrome (Chang et al., 2008), prolonged
survival of dopaminergic neurons in fly models of Parkinson’s
disease (Auluck et al., 2005; Faust et al., 2009) and lifespan
extension in fly models of Alzheimer’s disease (Rajendran et al.,
2008).
REPEAT EXPANSION-ASSOCIATED
NEURODEGENERATIVE AND
NEUROMUSCULAR DISEASES
As early as 1918, unstable nucleotide (microsatellite) repeat
expansion had already been identified as a mutational
mechanism underlying several human disease (Fleischer,
1918). Originally, only trinucleotide repeats were associated
with human diseases (Fu et al., 1991; La Spada et al., 1991). But
over the years, other disease-causing expandable microsatellite
repeats were gradually discovered including unstable tetra-,
penta-, and hexa-nucleotide repeats (Mirkin, 2007). Remarkably,
themajority of the repeat expansion-associated diseases (READs)
manifest with neurological and neuromuscular symptoms. Until
today, more than 20 neurodegenerative and neuromuscular
disorders have been linked with unstable nucleotide repeat
expansions in the human genome (Pearson et al., 2005;
Brouwer et al., 2009; Todd and Paulson, 2010; Polak et al.,
2013).
Repeat expansions can be coding or non-coding, and the
underlying mechanism of a READ may involve (1) loss-of-
function of wild-type protein, (2) gain-of-function of toxic RNAs,
or (3) gain-of-function of toxic proteins (Figure 1). Coding
expansion disorders usually result from smaller repeat copies
(few to tens of copies) that manifest in exon coding regions
of genes. This group of READs includes mostly polyglutamine
(polyQ) diseases like Huntington’s disease (HD) and several
forms of spinocerebellar ataxia (SCA), which typically involves
the translation of the gene products together with the repeat
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FIGURE 1 | Classification of READs and their types of toxicity. READs can be classified into coding and non-coding. A repeat expansion that occur in the
coding region of an affected gene may result in the loss-of-function of the wild type proteins, the gain-of-function of toxic RNAs, and the gain-of-function of toxic
proteins. In contrast, a repeat expansion in the non-coding region of an affected gene would not lead to immediate protein toxicity, but could involve the
loss-of-function of the wild type proteins and the gain-of-function of toxic RNAs. However, RAN translation may still occur in non-coding READs, which results in the
production of toxic repeat-containing proteins/peptides.
expansions into toxic proteins with gain-of-function (La Spada
et al., 1991; MacDonald et al., 1993; Orr et al., 1993; Kawaguchi
et al., 1994; Imbert et al., 1996; Pulst et al., 1996; Sanpei et al.,
1996; David et al., 1997; Zhuchenko et al., 1997; Nakamura et al.,
2001). In contrast, the non-coding expansions disorders typically
involve larger expansions (from ∼100 to 1000 copies), which
reside in the non-coding regions of genes, such as promoters,
introns or untranslated regions (UTRs). This groups includes
fragile X-associated tremor/ataxia syndrome (FXTAS), Friedrich’s
ataxia, C9-ALS/FTD, myotonic dystrophy types 1 and 2 (DM1
and DM2) and SCA8 (Brook et al., 1992; Montermini et al.,
1997; Jin et al., 2003; Mutsuddi et al., 2004; DeJesus-Hernandez
et al., 2011; Renton et al., 2011). Non-coding expansions usually
results in repeat-containing transcripts with gain-of-function
RNA toxicity. However, even non-coding expansions can still
be translated into toxic peptides by repeat-associated non-ATG
translation (Zu et al., 2011). Thus, the pathologies of READs
are complex, as both coding and non-coding repeat expansions
may involve a combination of mechanisms, including wild-type
proteins loss-of-function, toxic RNA gain-of-function, and toxic
protein gain-of-function.
RNA GAIN-OF-FUNCTION TOXICTY IN
READS AND ITS PATHOGENIC
MECHANISMS
The concept that RNA itself acts as a major toxic species in
neurodegenerative/neuromuscular disorders was first described
for DM1. DM1 is the most common form of muscular dystrophy
in adults, caused by an expanded CTG repeat in the 3′UTR of
the dystrophia myotonica protein kinase (DMPK) gene (Brook
et al., 1992; Fu et al., 1992; Mahadevan et al., 1992). Ribonuclear
foci were found to be forming in the nuclei of the affected cells,
and these foci contain the RNA transcripts from the CTG repeat
expansion (Taneja et al., 1995). In brief, the expanded repeats
localized at the foci in turn sequester endogenous RNA binding
proteins, impairing the alternatively splicing mechanisms and
leading to cellular toxicity and degeneration (Figure 2; Renoux
and Todd, 2012; Belzil et al., 2013; Fiszer and Krzyzosiak, 2013;
Nalavade et al., 2013). This is the “sequestration hypothesis” or
“alternative splicing impairment model,” which is one of the
most supported mechanisms of the emerging “RNA toxicity
model.” The ribonuclear foci are now a hallmark for most of the
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FIGURE 2 | Possible mechanisms of RNA toxicity in repeat expansion-associated diseases. Repeat expansion can occur in coding or non-coding regions of
affected genes. Bidirectional transcription results in both sense and antisense transcripts containing the repeats. Both sense and antisense expanded RNAs can form
ribonuclear foci. The foci may sequester RNA-binding proteins, such as MBNL1 in the case of DM1, leading to impairment of the alternative splicing and
nucleocytoplasmic transport machineries. The sense and antisense ssRNAs can anneal to form dsRNAs. ssRNAs can also form hairpin structures by themselves,
which are degradation resistant. Both dsRNAs and hairpin-forming RNAs may export the nucleus and be cleaved into sRNAs by Dicer. The sRNAs can then sequester
RNA-binding proteins, leading to splicing and nucleocytoplasmic transport impairment. For hexanucleotide repeats such as GGGCC in C9-ALS/FTD, the ssRNA may
form G-quadruplex structures. These structures facilitate DNA/RNA hybrid and impede transcription. They also form inclusions, leading to the sequestration of
RNA-binding proteins as well. Repeat-containing transcripts, whether in hairpin or G-quadruplex structures, can bind to NCL, inducing nucleolar stress and caspase
activation. Expanded transcripts that escape the nucleus associate themselves with ribosomes, leading to RAN translation. RAN translational products may form
inclusions, which disrupts nucleocytoplasmic transport, impedes the ubiquitin protease system and impairs the assembly, dynamics, and functions of membrane-less
organelles such as the nucleolar and stress granules. In neurons, the expanded transcripts may also be actively transported to neurites, resulting in neuritic branching,
and transport granule defects. It is postulated that the local translational machinery may also be disrupted.
Frontiers in Cellular Neuroscience | www.frontiersin.org 5 March 2017 | Volume 11 | Article 70
Koon and Chan Studying RNA Toxicity with Drosophila
READs associated with non-coding repeats (Wojciechowska and
Krzyzosiak, 2011). Some even coined the term “RNAopathies”
for these disorders due to the clear involvement of RNA toxicity.
Noted that, despite the consensus that the formation of foci
is a feature of pathogenesis, their role in pathogenesis is still
unclear. The original belief was that they could be toxic since they
harbor the toxic RNA transcripts. Yet, accumulating evidence
from DM1, DM2 and C9-ALS/FTD studies now suggests that
the foci per se, do not appear to be toxic, since cells with foci
do not necessarily degenerate (Houseley et al., 2005; Yu et al.,
2011, 2015; Mizielinska et al., 2014; Tran et al., 2015). The fact
that cells with the same amount of foci could very well be alive or
dying indicating that toxicity is not proportional to foci numbers
(Mizielinska et al., 2014; Tran et al., 2015). Thus, ribonuclear foci
could be neutral or even beneficial, at least in the beginning phase
of the disease progression.
An alternative mechanism of RNA toxicity is bidirectional
transcription. The original discovery for bidirectional
transcription came from a study on SCA8. SCA8 is a type
of spinocerebellar ataxia arises from a CTG expansion in the
3′ end of a non-protein coding RNA, Ataxin-8 Opposite Strand
(ATXN8OS; Koob et al., 1999). Its pathogenic mechanism was
thought to be similar to DM1 since both disorders involves a
CTG repeat. However, the antisense transcript, Ataxin-8, has a
short cryptic open reading frame that results in CAG repeats in
the glutamine reading frame (Moseley et al., 2006). Moreover,
nuclear polyQ inclusions were found, indicating that both toxic
RNA and toxic proteins gain-of-function were being produced
and could be involved in the pathogenesis of SCA8 (Moseley
et al., 2006). Bidirectional transcription was found in models
of DM1, FXTAS and SCA7, suggesting that it is a common
mechanism of RNA toxicity in READs (Cho et al., 2005; Ladd
et al., 2007; Sopher et al., 2011).
A third mechanism of RNA toxicity is nucleolar stress and
nucleocytoplasmic transport defects. Nucleolar stress is defined
as the cellular pathways used by the nucleolus to communicate
with cytosolic compartments in order to trigger apoptosis
(Boulon et al., 2010; Lindenboim et al., 2011). Hence, nucleolar
stress is a conserved and effective mechanism to eliminate
ribosome biogenesis-defective cells. It has been reported that
CAG repeat expansion in polyglutamine diseases interacts
directly with nucleolin (NCL), a nucleolar protein that regulates
rRNA transcription and ribosome biogenesis (Tsoi et al., 2012).
The CAG repeat-induced impairment of ribosome biogenesis
in turn increases the concentration of p53 in mitochondria,
disrupts the interaction between anti- and pro-apoptotic factors
such as Bcl-xl and Bak, causes cytochrome c release and caspase
activation, and eventually leads to cell death (Tsoi et al., 2012).
In polyQ diseases, the fact that CAG repeats-containing RNAs
are retained in the nucleus indicates defective nucleocytoplasmic
transport of the mutant transcripts (Tsoi et al., 2011). It was
reported that CAG repeats can directly bind to the U2 small
nuclear ribonucleoprotein auxiliary factor 65 (U2AF65), the fly
homolog of human U2AF50 that is involved in the nuclear
export of mRNA. U2AF65 is capable of forming a complex with
the nuclear export receptor NXF1 to regulate nucleocytoplasmic
transport of RNAs (Tsoi et al., 2011). Thus, the downregulation
of U2AF65 due to sequestration by CAG repeats results in the
nuclear accumulation of RNAs (Tsoi et al., 2011). Furthermore,
the researchers observed a neurodevelopmental downregulation
of U2AF65 protein levels in a mouse model of HD, suggesting
that the reduction in U2AF65 levels causes nuclear accumulation
of expanded CAG-containing transcripts in HD. Apart from
polyQ diseases, nucleocytoplasmic transport defects have also
been demonstrated in models of C9-ALS/FTD (Freibaum et al.,
2015; Zhang et al., 2015). These studies demonstrate the
involvement of the nucleolar stress and nucleocytoplasmic
transport defects in the RNA toxicity-mediated pathogenesis of
READs.
A forth mechanism of RNA toxicity is mediated by hairpin-
forming single stranded RNAs (ssRNAs) and double-stranded
RNAs (dsRNAs) containing the expanded repeats. Both of
them would eventually lead to the generating of toxic repeat-
containing small RNAs (sRNAs), which is the true culprit
of this mechanism of RNA toxicity in READs. It is known
that hairpin structures can be formed by single stranded
CAG repeats in polyQ diseases and CGG repeats in FXTAS
(Sobczak et al., 2003, 2010). Complex secondary structures like
hairpin loops can significantly alter the transcripts’ processing,
transport, translation, and interactions with RNA binding
proteins. Hairpin structures also strongly protects the RNAs
from attacks by nucleases, rendering them more resistant to
degradation (Sobczak et al., 2010). Hence, the hairpin structure
itself already conveys a type of toxicity. However, the more
severe consequences come from the fact that it facilitates the
production of sRNAs via the RNAi machinery. Dicer is an RNase
III family ribonuclease that cleaves double-stranded precursor
RNAs to generate sRNAs, and is a key enzyme involved in RNAi
(Bernstein et al., 2001). Since expanded ssRNAs in READs form
double-stranded hairpin structures, they are valid substrates of
Dicer, and will be cleaved into sRNAs. Even though these repeat-
containing sRNAs cannot form ribonuclear foci, they are still
capable of binding to key proteins of the alternative splicing
machinery, such asMBNL1, and cause defects in RNA processing
(Mykowska et al., 2011). sRNAs with as few as seven CAG repeats
have been shown to induce caspase activation and cellular toxicity
in a disease model of HD (Bañez-Coronel et al., 2012). It has been
reported that the knockdown of Dicer expression can reduce
sRNA in HD and SCA1 models, supporting the involvement of
RNAi in the sRNA-induced toxicity of READs (Krol et al., 2007;
Bañez-Coronel et al., 2012). Since bidirectional transcription
is common with repeat expansions, the transcribed sense and
antisense strands may form double-stranded RNAs (dsRNAs).
Once again, dsRNA is a substrate of Dicer, thus it becomes a
source of sRNAs. This mechanism was demonstrated in two
Drosophila studies. One showed that that dsRNAs comprising
CAG/CUG repeats can be a source of cellular toxicity via the
Dicer pathway (Lawlor et al., 2011). The other study showed that
the co-expression of CAG and CUG repeats results in enhanced
RNA toxicity in a Dicer-dependent manner by generating more
sRNAs, which impedes the expression of CAG-containing genes,
such as Ataxin-2 and TATA-binding protein (TBP; Yu et al.,
2011). Therefore, both ssRNA hairpins and dsRNAs can be a
source of harmful sRNAs that results in cellular toxicity. For
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hexanucleotide repeat expansions such as GGGGCC in C9-
ALS/FTD, the single stranded RNA repeats can even form G-
quadruplex structures (Reddy et al., 2013; Haeusler et al., 2014).
G-quadruplex structures can induce a number of detrimental
consequences in the cell including transcription impairment,
formation of inclusions and sequestration of ribonucleoproteins
to impeded alternative splicing and induce nucleolar stress
(Haeusler et al., 2014; Conlon et al., 2016).
A fifth mechanism which non-coding expanded transcripts
lead to cellular toxicity is by repeat-associated non-ATG (RAN)
translation. Normally, protein synthesis is initiated by the start
codon ATG, which leads to the translation of mRNA. Ranum
and colleagues have discovered a novel mechanism which repeat
expansions in READs can bypass the need of a start codon and
mediate RAN translation of the repeat-containing transcripts
(Zu et al., 2011). In RAN translation, the accumulated expanded
repeat RNAmay undergo protein translation in all three possible
reading frames, resulting in the production of proteins consisting
of different amino acid combinations (Zu et al., 2011). It has
been shown in SCA8, FXTAS, and C9-ALS/FTD that the protein
products from RAN translation are highly toxic and play an
significant role in pathogenesis (Zu et al., 2011; Todd et al., 2013;
Mizielinska et al., 2014; Freibaum et al., 2015; Oh et al., 2015;
Tran et al., 2015; Lee et al., 2016).
A sixth mechanism of RNA toxicity involves the expanded
RNAs being actively transported to neurites by transport
granules, which in turn induces a neuritic branching defect in
neurons (Burguete et al., 2015). This could be explained by the
fact that the expanded RNA-bound transport granules cannot
function normally, and the transport defects possibly interfere
with the local translational machinery as well (Burguete et al.,
2015).
MODELING THE RNA TOXICITY OF
REPEAT EXPANSIONS IN DROSOPHILA
Recent work in Drosophila has begun to shed light on the
emerging “RNA toxicity model.” One of the earliest Drosophila
studies that demonstrated this model was pioneered by Rebay
and colleagues in the pathogenesis of SCA8 (Mutsuddi et al.,
2004). Unlike most other types of SCA, SCA8 is associated with
a CTG repeat expansion within a non-coding region (Koob
et al., 1999). A Drosophila model of SCA8 was developed by
overexpressing the non-coding transcript of the human SCA8
locus in the fly eye, which results in retinal degeneration
(Mutsuddi et al., 2004). The Drosophila RNA binding protein
genes, staufen,muscleblind (Mbl), split ends, andCG3249, were all
subsequently identified as genetic modifiers of this degeneration,
suggesting that RNA rather than expanded protein is the source
of toxicity (Mutsuddi et al., 2004). DM1 is another non-coding
READ demonstrated to be caused by RNA toxicity. DM1 is
associated with a CUG repeat expansion in the 3′ UTR of the
DMPK gene. A Drosophila model of DM1 was established by
expressing non-coding CUG repeats in either theDrosophila eyes
or muscles. Degeneration was observed in both cases, indicating
the presence of toxic RNA gain-of-function (de Haro et al., 2006).
In the case of FXTAS, a CGG repeat expansion occurs in the 5′
UTR of the FMR1 gene. In Drosophila, it was reported that the
expression of non-coding CGG repeats was sufficient to induce
retinal degeneration in the absence of expressed proteins (Jin
et al., 2003). All these studies in Drosophila support the notion
that RNA toxicity play a significant role in the pathologies of
many READs. More importantly, these studies also demonstrate
the fruit fly as an excellent model for studying human READs and
RNA toxicity. Currently, fly models have been established for at
least 13 different READs (Table 1). Below, we will cover a number
of READs with RNA toxicity and highlight the discoveries made
using their correspondingDrosophilamodels. These READswere
selected base on the following two criteria: (i) It has been shown
that gain-of-function RNA toxicity contributes to the pathology
of these diseases, and (ii) there are established Drosophilamodels
for studying the RNA toxicity of these diseases.
Drosophila Models of Polyglutamine
Diseases
Polyglutamine diseases are caused by the expansion of unstable
CAG repeats in the protein-coding region of the respective
disease gene. The CAG repeats are translated into a string of
glutamine in normal functioning proteins. Patients of polyQ
diseases often develop progressive neurodegeneration and motor
impairment (Rub et al., 2013). PolyQ diseases include HD,
spinobulbar muscular atrophy (SBMA; a.k.a. Kennedy disease),
dentatorubral-pallidoluysian atrophy (DRPLA), spinocerebellar
ataxia (SCA) types 1, 2, 3 (a.k.a. Machado-Joseph disease or
MJD), 6, 7, and 17 (La Spada et al., 1991; MacDonald et al.,
1993; Orr et al., 1993; Kawaguchi et al., 1994; Imbert et al.,
1996; Pulst et al., 1996; Sanpei et al., 1996; David et al., 1997;
Zhuchenko et al., 1997; Nakamura et al., 2001; Warrick et al.,
2005). HD is caused by an abnormal expansion of CAG repeats
in exon 1 of theHuntingtin (HTT) gene (MacDonald et al., 1993).
For SBMA, the CAG repeat expansion lies in the N-terminus
of the coding region of the androgen receptor gene (La Spada
et al., 1991; Zhou et al., 1994). For DRPLA, the unstable
CAG expansion occurs in the middle of the Atrophin-1 gene
(Koide et al., 1994). As for SCA1, 2, 3, 6, 7, and 17, the
CAG expansion are located in the coding regions of Ataxin-
1, Ataxin-2, Ataxin-3, CACNA1A, Ataxin-7, and TATA-binding
protein (TBP), respectively (Nakamura et al., 2001; Rub et al.,
2013). Despite the fact that the CAG repeat expansions in these
polyQ diseases affect different genes, there are several shared
features among the majority of polyQ diseases. First, a common
hallmark is the abnormal aggregation of nuclear inclusions
containing the mutant proteins. These inclusions that contain
abnormal aggregated proteins were once regarded as a potential
cause of cellular toxicity. However, a number of studies have
demonstrated that the formation of inclusions could actually be a
cellular protective response tomitigate the toxicity (Stefanis et al.,
2001; Petrucelli et al., 2002; Arrasate et al., 2004). Until today,
the general belief is that the formation of aggregates is a dynamic
process. Smaller oligomeric inclusions are likely to toxic, whereas
the large aggregates might actually be protective (Ross and
Poirier, 2005). Further investigations will be required to elucidate
their true nature. Second, the CAG repeat length is inversely
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TABLE 1 | Published transgenic Drosophila lines for modeling repeat expansion-associated diseases.
READ Affected human gene Expansion region of the
human gene
Nucleotide
repeat
Established Drosophila lines for modeling READs
(under UAS control)
HD Huntingtin (HTT ) Coding region (Exon 1) CAG With an exon1-derived HTT fragment
(Jackson et al., 1998):
HTT1−142-Q2
HTT1−142-Q75
HTT1−142-Q120
(Steffan et al., 2001):
Htt-ex1p-Q20
Htt-ex1p-Q93
UAS-Q48 + myc/flag
(Doumanis et al., 2009):
Nhtt-18Q-EGFP
Nhtt-48Q-EGFP
Nhtt-98Q-EGFP
Nhtt-152Q-EGFP
Nhtt-48Q-EGFPNLS
With a HTT fragment of amino acids 1-336
(Kaltenbach et al., 2007):
128Q-htt[M64]
With a HTT fragment of amino acids 1-548
(Lee et al., 2004):
Htt-Q0
Htt-Q128
With a HTT fragment of amino acids 1-588
(Weiss et al., 2012):
mRFP-Htt-Q15
mRFP-Htt-Q138
EGFP-Htt-Q15
EGFP-Htt-Q138
EGFP-Htt-Q15-mRFP
EGFP-Htt-Q138-mRFP
Htt1−81-Q96-GFP (with HTT exon 1 amino acids 1-81)
With full length HTT (3144 amino acids)
(Romero et al., 2008):
16Q-httFL
128Q-httFL
SBMA Androgen receptor (AR) Coding region (N-terminus) CAG (Takeyama et al., 2002):
AR-Q0
AR-Q52
DRPLA Atrophin-1 (AT1) Coding region CAG (Nisoli et al., 2010):
At-1-wt
At-1-65Q
At-1-65∆C
Atro-wt
Atro-75QN
Atro-66QC
SCA1 Ataxin-1 (ATXN1) Coding region CAG (Fernandez-Funez et al., 2000):
Ataxin-1 Q30
Ataxin-1 Q82
SCA3 (MJD) Ataxin-3 (ATXN3) Coding region CAG (Warrick et al., 1998):
SCA3tr-Q27
SCA3tr-Q78
(Warrick et al., 2005):
SCA3-Q27
SCA3-Q78
SCA3-Q84
SCA3-Q27-UIM*
SCA3-Q80-UIM*
(Continued)
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TABLE 1 | Continued
READ Affected human gene Expansion region of the
human gene
Nucleotide
Repeat
Established Drosophila lines for modeling READs
(under UAS control)
SCA3-Q27-C14A
SCA3-Q88-C14A
SCA3-delta
(Li et al., 2008):
SCA3tr-Q61
SCA3tr-Q78CAA/G
DsRed-CAG0
DsRed-CAG100
DsRed-CAG250
SCA6 CACNA1A Coding region (exon 47) CAG (Tsou et al., 2015):
α1ACT-Q11
α1ACT-Q70
(Tsou et al., 2016):
α1ACT-Q33
SCA7 Ataxin-7 (ATXN7) Coding region CAG (Jackson et al., 2005):
SCA7-Q90
(Latouche et al., 2007):
ATXN7T-Q10
ATXN7T-Q102
SCA8 ATXN8OS (non-protein coding
Ataxin-8 opposite strand)
3′UTR CTG (Mutsuddi et al., 2004):
SCA8(CTG)9
SCA8(CTG)112
SCA17 TATA binding protein (TBP) Coding region CAG (Ren et al., 2011):
TBP-Q34
TBP-Q54
TBP-Q80
FXTAS Fragile X mental retardation 1 (FMR1) 5′UTR CGG (Jin et al., 2003):
(CGG)60-GFP
(CGG)90-GFP
(Todd et al., 2013):
5′UTR: (CGG)100-(+1)-ATG-GFP
5′ATG: ATG-(CGG)100-(+1)-ATG-GFP
3′UTR: ATG-GFP-STOP-(CGG)100-(+1)
5′Stop: STOP-(CGG)100-(+1)-ATG-GFP
DM1 Dystrophia myotonica protein kinase
(DMPK)
3′UTR CTG (Houseley et al., 2005):
GFP-(CTG)11
GFP-(CTG)48
GFP-(CTG)56
GFP-(CTG)162
(de Haro et al., 2006):
i(CTG)480
(Garcia-Lopez et al., 2008):
(CTG)60
i(CTG)480
(Yu et al., 2011):
(CTG)19
(CTG)130
(CTG)200
(CTG)230
(CTG)250
(CTG)270
(Continued)
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TABLE 1 | Continued
READ Affected human gene Expansion region of the
human gene
Nucleotide
Repeat
Established Drosophila lines for modeling READs
(under UAS control)
(Picchio et al., 2013):
i(CTG)240
i(CTG)480
i(CTG)600
i(CTG)960
(“i” indicates “interrupted repeats”.)
DM2 Zinc finger protein 9 (ZNF9) Intron 1 CCTG (Yu et al., 2015):
(CCTG)16
(CCTG)200
(CCTG)475
(CCTG)525
(CCTG)700
(CCTG)720
C9ORF72-associated
ALS-FTD
C9ORF72 Promoter and intron 1 GGGGCC (Xu et al., 2013):
(GGGGCC)3
(GGGGCC)30
(Mizielinska et al., 2014):
(GGGGCC)3 Pure
(GGGGCC)36 Pure
(GGGGCC)36 RO
(GGGGCC)108 RO
(GGGGCC)288 RO
(PA)36
(GA)36
(PR)36
(GR)36
(Freibaum et al., 2015):
(GGGGCC)8
(GGGGCC)28
(GGGGCC)58
GFP-(GP)47
GFP-(GA)50
GFP-(GR)50
(Tran et al., 2015):
(GGGGCC)5R (flanked by human intronic and exonic
sequences)
(GGGGCC)80R (flanked by human intronic and exonic
sequences)
(GGGGCC)160R (flanked by human intronic and exonic
sequences)
UIM* indicates that the highly conserved serine resides in the ubiquitin interaction motifs are mutated to alanine to disrupt ubiquitin binding.
proportional to the age of disease onset. Longer CAG lengths
cause earlier onset of polyQ diseases (Zoghbi and Orr, 2000; Ross
and Poirier, 2005). This is because once the polyQ repeat length
exceeds a pathogenic threshold (typically ∼35), the mutant
proteins are likely to mis-fold into abnormal conformations that
can resist normal cellular degradation machineries such as the
ubiquitin-proteasome system (Sisodia, 1998; Chan et al., 2000;
Ross and Poirier, 2005).
PolyQ diseases were among the first neurodegenerative
diseases modeled in Drosophila. The earliest Drosophila models
include HD and SCA3. Zipursky and colleagues fused a
truncated form of wild-type human HTT with a polyQ tract
of 2, 75, or 120 repeats (HTT1−142-Q2, HTT1−142-Q75 and
HTT1−142-Q120; Jackson et al., 1998), whereas Bonini and
colleagues generated truncated forms of human Ataxin-3 with
a polyQ tract of 27 or 78 repeats (SCA3tr-Q27 and SCA3tr-
Q78) (Warrick et al., 1998). When expressed in the fly eye,
both studies found that only the constructs with pathogenic
lengths (HTT1−142-Q75, HTT1−142-Q120, and SCA3tr-Q78)
induced nuclear inclusions and degeneration, recapitulating the
pathogenic features of polyQ diseases. These studies, for the first
time, demonstrated thatD.melanogaster can be a powerful model
to study human neurodegenerative diseases. Subsequently, more
Drosophilamodels of HD and SCA3 (Steffan et al., 2001; Lee et al.,
2004; Warrick et al., 2005; Kaltenbach et al., 2007; Li et al., 2008;
Romero et al., 2008; Doumanis et al., 2009; Weiss et al., 2012), as
well as other polyQ diseases, including SCA1 (Fernandez-Funez
et al., 2000), SCA6 (Tsou et al., 2015, 2016), SCA7 (Jackson et al.,
2005; Latouche et al., 2007), SCA17 (Ren et al., 2011), SBMA
(Takeyama et al., 2002; Pandey et al., 2007; Nedelsky et al., 2010),
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and DRPLA (Nisoli et al., 2010; Napoletano et al., 2011) were
developed. All these studies demonstrate that polyQ diseases, in
most cases, can yield parallel neural degenerative effects in the
fruit fly.
Besides protein toxicity, there is now substantial evidence
for RNA toxicity in polyQ diseases as well. One of the most
compelling studies was performed by Bonini and colleagues in
the studying of SCA3 in Drosophila (Li et al., 2008), which they
showed that the expression of both translated and untranslated
CAG repeats caused neural degeneration, whereas the expression
of CAA-interrupted CAG repeats resulted in significantly less
pronounced neurodegenerative effects (Li et al., 2008). Similar
to CAG repeats, CAA repeats also encode for glutamine. Yet
CAA repeats are unable to form a hairpin structure (Sobczak
et al., 2010). As the hairpin structure contributes to CAG
repeat-containing sRNA generation, it is one of the major
mechanisms of RNA toxicity (Krol et al., 2007; Bañez-Coronel
et al., 2012). Therefore, the above findings suggest that RNA
toxicity contributes significantly to neurodegeneration in SCA3.
Apart from hairpin structures, it is also known that CAG
repeats in polyQ diseases, similar to CUG repeats in DM1, can
form ribonuclear foci that colocalize with RNA-binding proteins
such as muscleblind-like 1 (MBNL1), and cause misregulation
in alternative splicing (Ho et al., 2004, 2005; Yuan et al.,
2007; Hsu et al., 2011; Mykowska et al., 2011; Wang et al.,
2011). In fact, Krzyzosiak and colleagues demonstrated that
expanded CAG repeats present in HTT and ATXN3 transcripts
colocalize with MBNL1 in ribonuclear foci, further confirming
the accumulation of mutant RNA in the nucleus (Mykowska
et al., 2011). Interestingly, although both CAG and CUG repeats
form foci, sequester MBNL1 and affect alternative splicing, the
splicing of some pre-mRNAs are only affected by CUG repeats
but not CAG repeats (Ho et al., 2005). Hence, despite the
overlapping mechanisms of involvement of MBNL1, there are
still differences in how splicing is disrupted by CAG repeats in
polyQ diseases and CUG repeats in DM1.
In addition to the sequestering of RNA-binding proteins, RNA
toxicity in polyQ diseases may also arise from the perturbation of
RNA export mechanisms and the induction of nucleolar stress
(Tsoi et al., 2011, 2012). In the Drosophila model of SCA3, it
has been demonstrated that U2AF65, which is involved in the
nuclear export of mRNA, can bind directly to CAG repeats and
form a complex with the nuclear export receptor NXF1 (Tsoi
et al., 2011), and the downregulation of U2AF65 correlates with
the nuclear accumulation of expanded CAG RNA (Tsoi et al.,
2011). Apart from U2AF65, CAG repeat expansion can also
interact directly withNCL, and induce apoptosis by the activation
of the nucleolar stress pathway (Tsoi et al., 2012). NCL is an
essential protein involved in RNA polymerase I-mediated rRNA
transcription in the nucleolus. The binding of expanded CAG
repeats perturbs ribosome biogenesis, which in turn increases the
levels of mitochondrial p53, and causes cytochrome c release and
caspase activation (Tsoi et al., 2012).
Utilizing the established fly models of SCA3, much advances
have been made in the search of genetic modifiers of polyQ
toxicity and CAG-repeat RNA toxicity. Using the fly model of
SCA3, HSP70 was found to colocalize with polyQ inclusion
bodies, and was identified as a strong suppressor of polyQ toxicity
(Warrick et al., 1999; Chan et al., 2000). A genome-wide genetic
screen was also performed, and identified a number of other
chaperones and ubiquitin pathway-related molecules as genetic
modifiers of polyQ toxicity (Bilen and Bonini, 2007). As for
RNA toxicity in SCA3, a microarray analysis was performed
to search for genes which expression levels are affected by
CAG repeats (Shieh and Bonini, 2011). Several iron ion binding
and nucleotide binding molecules were found to be affected.
Interestingly, HSP70, co-chaperone Tpr2, the transcriptional
regulator Dpld, and the RNA-binding protein Orb2 were able
to modify both polyQ and RNA toxicity, suggesting that there
are overlapping mechanisms of RNA and protein based toxicity
(Shieh and Bonini, 2011).
All the above studies demonstrated that both protein and
RNA toxicity contribute to neurodegeneration in polyQ diseases,
and both types of toxicity can involve a number of different
underlying molecular mechanisms which can be studied using
Drosophilamodels.
Drosophila Models of Fragile X Syndrome
and Fragile X-Associated Tremor/Ataxia
Syndrome
Fragile X syndrome (FXS) is the most common cause of inherited
intellectual disability, often associated with autism spectrum
disorders (Bhakar et al., 2012; Santoro et al., 2012). The disease
was first described as mental retardation segregated in X-linked
fashion (Martin and Bell, 1943). The chromosomal variation
was later mapped to Xq27.3 and was dubbed “the fragile X
chromosome” (Harrison et al., 1983). In FXS, a trinucleotide
CGG expansion in the 5′ UTR of the FMR1 gene results in
transcriptional silencing and loss of the corresponding protein,
Fragile X Mental Retardation Protein (FMRP; Fu et al., 1991;
Kremer et al., 1991). Normal alleles contain 6–55 repeats,
premutation alleles contain 55–200, and the disease alleles
contain over 200 repeats. FMRP is an RNA-binding protein
which negatively regulates the translation of mRNAs, especially
at synapses in neurons. Loss of FMRP impairs synaptic plasticity,
which is believed to be the molecular basis for the intellectual
disability in FXS patients (Bassell and Warren, 2008).
The Drosophila genome contains a highly-conserved FMR1
gene, dfmr1 (Wan et al., 2000). The first Drosophila FXS model
was generated by imprecise excision of a P-element located
upstream of the dfmr1 locus to produce a null mutant (Zhang
et al., 2001). Subsequently, a wide array of dfmr1 alleles and
transgenes have been created to facilitate FXS research in this
classic genetic model (Dockendorff et al., 2002; Morales et al.,
2002; Lee et al., 2003). Overexpression of either the human FMRP
(FMR1 gene) or the native Drosophila dFMRP (dfmr1 gene) fully
rescues all detectable disease-like phenotypes in the Drosophila
FXS model (Coffee et al., 2010), confirming the evolutionary
conserved functions of FMR1 in the nervous system.
In 2003, Warren and colleagues expressed 90 CGG
repeats with a reporter in the Drosophila compound eye
and demonstrated retinal degeneration in the absence of
expressed proteins (Jin et al., 2003). These findings suggest
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that, apart from loss-of-function of wild-type FMRP, there
exists a toxic RNA gain-of-function component associated with
the repeat expansion that occurs at the 5′ UTR of the FMR1
gene. This RNA toxicity causes a late-onset neural degeneration
phenotype, which is now identified as Fragile X-associated
tremor/ataxia syndrome (FXTAS). While FXS is mostly caused
by the loss-of-function of wild-type FMRP, which results in
neurodevelopmental and behavioral disorders characterized by
mental retardation, autism, anxiety and mood instability, FXTAS
is mostly caused by the CGG repeat expansion that produces
gain-of-function RNA toxicity in the CNS, which results in a late-
onset neurodegenerative disorder, characterized by progressive
intention tremor, gait ataxia, parkinsonism, and cognitive
decline (Jacquemont et al., 2007; Tassone and Hagerman, 2012).
FXTAS is found mostly in male premutation carriers after
the age of 50 (Tassone and Hagerman, 2012). Although at a
much lower rate, female carriers may also develop FXTAS. The
neuropathological hallmark of FXTAS is the ubiquitin-positive
intranuclear inclusion, present in both neurons and astrocytes
throughout the brain (Greco et al., 2002). Warren and colleagues
found that in their (CGG)90 fly model of FXTAS, the inclusion
bodies in the degenerating neurons contain HSP70 (Jin et al.,
2003). Furthermore, when they overexpress HSP70, the CGG
repeat-induced degeneration was suppressed (Jin et al., 2003),
which is similar to the case of SCA3 where HSP70 also presents
suppressor activity of CAG repeat-induced toxicity (Warrick
et al., 1999; Chan et al., 2000). Two subsequent studies have
utilized thisDrosophilamodel of FXTAS and identified a number
of tropomyosin and RNA-binding proteins as genetic modifiers
of the degeneration phenotype (Jin et al., 2007; Sofola et al.,
2007). These findings strongly suggest that the RNA processing
machinery play an important role in the pathogenesis of
FXTAS. Interestingly, both studies have found that one of these
RNA-binding proteins that interacts with the CGG repeats to
be CUG-binding protein 1 (CUGBP1), which is a protein also
involved in the pathogenesis of another READ, DM1. Indeed,
CGG repeats have been shown to form RNA hairpin structures
in vitro, similar to CAG repeats in SCA3 and CUG repeats in
DM1 (Sobczak et al., 2003, 2010). Thus, it is possible that these
RNA-binding proteins bind to the CGG repeats in an effort to
disassemble these potentially toxic hairpins, but in the process
neglected their other cellular functions.
Recent studies in neurodegenerative and neuromuscular
diseases have advanced toward the investigation of cellular
transcriptional and translational profiles. Nelson and colleagues
discovered that mice Purkinje neurons ectopically expressing 90
CGG repeats exhibit a dramatic change in their translational
profile even prior to the onset of CGG repeat-induced
phenotypes (Galloway et al., 2014). Interestingly, the Tardbp
gene, which encodes the TDP-43 protein was found to be
reduced in Purkinje neurons (Galloway et al., 2014). TDP-43
is a RNA-binding protein commonly found in the inclusion
bodies in ALS (Xu and Yang, 2014). In the fly model of FXTAS,
overexpression of TDP-43 suppresses neurodegeneration in the
fly eye, whereas knockdown of Drosophila TDP-43 results in
enhancement of the degeneration phenotype (Galloway et al.,
2014). Todd and colleagues also discovered that overexpression
of TDP-43 was capable of suppressing CGG repeat toxicity (He
et al., 2014). Interestingly, they found that the CGG repeat RNA
levels and RAN translation levels are both not affected by TDP-
43. Instead, they found TDP-43 alters the composition, behavior
and distribution of multimeric RNA-binding protein complexes,
preventing the sequestration of hnRNP A2/B1, and rescuing
the alternative splicing machinery (He et al., 2014). They also
tested an ALS mutant form of TDP-43, which can still bind to
hnRNP A2/B1, and yet it failed to rescue the CGG repeat toxicity,
suggesting that wild type TDP-43 functions are necessary for this
suppression of CGG repeat toxicity (He et al., 2014).
In the study above by Nelson and colleagues, the researchers
discovered ∼500 transcripts that are differentially associated
with ribosomes in the CGG repeats-expressing Purkinje neurons
(Galloway et al., 2014). Theoretically, if ribosomes are recruited
to the repeat expansions, translation of the repeats would be
facilitated. Indeed, RAN translation has also been demonstrated
in FXTAS models. Paulson and colleagues have demonstrated
that CGG repeats lead to RAN translation of a cryptic
polyglycine-containing protein, FMRpolyG, which is present in
inclusion bodies in FXTAS fly models, mouse models and FXTAS
patient brains (Todd et al., 2013). The researchers constructed a
Drosophila line expressing CGG repeats preceded by a stop codon
just 5′ to the repeats. Production of FMRpolyG is inhibited by
this stop codon, but the CGG repeat-containing RNA remained.
This line gave rise to a much milder phenotype comparing with
CGG repeats without the stop codon, indicating RAN translated
FMRpolyG contribute to toxicity (Todd et al., 2013). A follow-up
Drosophila study revealed that FMRpolyG impairs the ubiquitin
protease system (Oh et al., 2015). Inhibition of RAN translation
can reduce inclusion formation and attenuate the impairment of
the ubiquitin protease system (Oh et al., 2015).
Taken together, these studies suggest that FXTAS pathogenesis
may be mechanistically related to the polyQ diseases, myotonic
dystrophy, and ALS. Thus, different READs that arise from
different causes may converge and share some common
molecular mechanisms in their pathogenesis.
Drosophila Models of Myotonic Dystrophy
Type 1 and Type 2
Myotonic dystrophy is the most common form of muscular
dystrophy affecting about 1 in 8,000 adults (Harper, 2001). It is
a multisystemic, autosomal dominant neuromuscular disorder,
characterized by progressive myotonia (inability of muscles
to relax after contraction), muscle degeneration, iridescent
cataracts, cardiac arrhythmias, testicular atrophy, and symptoms
of neuropathology (Harper, 2001). DM1 is caused by a CTG
repeat expansion in the 3′ UTR of the DMPK gene, which
encodes a serine-threonine protein kinase (Brook et al., 1992).
Normal individuals typically have fewer than 37 CTG repeats,
whereas DM1 patients can range from 50 to 4,000 repeats
(Thornton et al., 1994). The mutant transcripts containing CUG
repeats fold into RNA hairpins that are retained in the nucleus
(Davis et al., 1997; Koch and Leffert, 1998), whereas the levels
of DMPK protein are correspondingly reduced (Fu et al., 1993).
Dmpk knockout mice have reduced force generation in skeletal
muscles (Reddy et al., 1996) and abnormal cardiac conduction
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(Berul et al., 1999), which suggests that the loss of DMPK
function may contribute to at least the muscle weakness and
cardiac defects in DM1. However, Dmpk knockout mice do not
display myotonia and muscle degeneration (Reddy et al., 1996),
which are some of the hallmark features of DM1. In contrast,
transgenic mice expressing expanded CTG repeats display
myotonia, degeneration, and several other muscular pathological
abnormalities (Mankodi et al., 2000). These results demonstrated
that the expanded CTG repeats by themselves could account
for at least some of the major pathological features of DM1
independent of the DMPK locus. It was eventually demonstrated
that the CUG-repeat-containing transcripts retained in the
nucleus aggregate into ribonuclear foci (Taneja et al., 1995;
Mankodi et al., 2000). These foci binds to RNA-binding proteins
like MBNL1 and CUGBP1 (Miller et al., 2000; Kanadia et al.,
2003), which in turn compromises the RNA splicing machinery
(Philips et al., 1998; Ho et al., 2004) and even disrupts the
regulation of transcription (Ebralidze et al., 2004).
Monckton and colleagues developed a Drosophila model of
DM1 by fusing 162 non-coding CTG repeats to a reporter
gene and overexpressing the repeats in fly muscles (Houseley
et al., 2005). Although 162 CUG repeats results in the formation
of ribonuclear foci, it did not result in detectable cellular
toxicity. Botas and colleagues further examined the effect of
non-coding CUG repeats by increasing the repeat number
to 480 (interrupted repeats). With this amount of repeats,
vacuolization and degeneration were then detected in adult fly
muscles (de Haro et al., 2006). Expression of 480 CUG repeats
in the adult eye also results in disorganization of ommatidia
and reduction of the eye size, suggesting gain-of-function RNA
toxicity (de Haro et al., 2006; Garcia-Lopez et al., 2008).
Similar to mammals, the molecular mechanisms of this CUG-
induced toxicity involve the sequestration of Drosophila Mbl
and CUGBP1 by the CUG repeat-containing ribonuclear foci,
resulting in defective alternative splicing (de Haro et al., 2006;
Garcia-Lopez et al., 2008). However, in contrast to CUGBP1,
which has been shown to interact with CGG repeats and is
involved in FXTAS, no evidence for the genetic interaction
of muscleblind family proteins and CGG repeats had been
found in Drosophila (Sofola et al., 2007). Thus, although the
pathogenesis of FXTAS and myotonic dystrophy may share some
commonalities, there are certainly distinct mechanisms for the
two READs as well. Utilizing this fly model of DM1, Botas
and colleagues identified SMAUG, a myosin-binding protein, as
suppressor of CUG repeat-induced toxicity (de Haro et al., 2013).
SMAUG interacts genetically and physically with CUGBP1, and
its overexpression restores the translational activity of CUGBP1
in this DM1 model (de Haro et al., 2013).
Refinements of the DM1 fly models were made in some recent
studies, with new discoveries being yield. Jagla and colleagues
constructed fly lines with 240, 480, 600, and 960 interrupted
CTG repeats, and established a novel Drosophila larval model of
DM1 (Picchio et al., 2013). Using this model, they constructed
transcription profiles of DM1, and uncovers a number of splice-
independent deregulated genes (Picchio et al., 2013). Bonini and
colleagues cloned 19, 130, 200, 230, 250, and 270 uninterrupted,
pure CTG repeats into the 3′ UTR of the DsRed gene to
better recapitulate the pathological condition of the disease (Yu
et al., 2011). Repeat length-dependent toxicity was detected
when the repeat length reaches 200 or more. Interestingly,
the researchers discovered that there was a synergistic effect
on the enhancement of toxicity when CAG repeats are co-
expressed together with CUG repeats due to the biogenesis of
sRNAs (Yu et al., 2011). This enhancement was Dicer-dependent,
indicating the involvement of the RNAi machinery (Yu et al.,
2011).
DM2 is caused by a tetranucleotide CCTG repeat expansion
in the first intron of the zinc finger protein 9 (ZNF9) gene,
which encodes a RNA-binding protein (Liquori et al., 2001).
Affected individuals can have 75 to 11,000 CCTG repeats, with
a mean of ∼5,000 (Liquori et al., 2001). DM2, much like DM1,
involves the aggregation of expanded mutant transcripts into
ribonuclear foci, which interfere with key molecules of the
splicing machinery, such as MBNL1 and CUGBP1 (Liquori et al.,
2001). Although DM1 and DM2 share much similarities in their
pathologies, DM2 has less-pronounced neurological involvement
and cannot be congenital (Minnerop et al., 2011). To develop a
fly model of DM2, Bonini and colleagues generated constructs
with 16, 200, 475, 525, 700, and 720 non-coding CCTG repeats
to investigate length-dependent RNA toxicity (Yu et al., 2015).
Expression of 200 repeats was sufficient to induce the formation
of ribonuclear foci, but impairment of alternative splicing and
retinal degeneration were only observed when the repeat length
was 475 or above. In addition, the researchers demonstrate that
the expression of two different isoforms of MBNL1 (with or
without the linker region between zinc finger domain 2 and 3)
can lead to cleavage of non-coding CUG or CCUG RNA repeats,
andmildly rescue CCUG-induced degeneration in the fly eye (Yu
et al., 2015).
Drosophila Models of
C9ORF72-Associated Amyotrophic Lateral
Sclerosis/Frontotemporal Dementia
Amyotrophic lateral sclerosis (ALS), also known as Lou
Gehrig’s disease, is an adult-onset neurodegenerative disease
characterized by the progressive loss of motor neurons in the
cortex, brainstem, and spinal cord. Symptoms include the loss
of movement control, difficulty in speaking, swallowing, and
eventually breathing, which leads to fatality (Kurtzke, 1982). ALS
affects about 2 per 100,000 individuals in Europe and the United
States (Kiernan et al., 2011). Most cases of ALS are deemed
sporadic, but 5–10% cases are inherited (Hand and Rouleau,
2002). Mutations from more than 20 different genes have been
linked to familial ALS (Chen et al., 2013; Ajroud-Driss and
Siddique, 2015). Despite some of these identified genes play a
role in RNA metabolism and axonal trafficking (Strong, 2010;
Ikenaka et al., 2012; Millecamps and Julien, 2013; Droppelmann
et al., 2014), most of them apparently do not function in the same
molecular pathway, complicating the underlying mechanisms
of the disease (Chen et al., 2013; Ajroud-Driss and Siddique,
2015).
In 2011, the expansion of a GGGGCC hexanucleotide repeat
in the non-coding region of C9ORF72 was found to be associated
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with ALS combined with frontotemporal dementia (DeJesus-
Hernandez et al., 2011; Renton et al., 2011). Frontotemporal
dementia is a group of disorders caused by the progressive loss
of neurons predominantly at the frontal and/or temporal lobes of
the brain resulting in cognitive and behavioral impairment, and
is one of the most common causes of dementia second only to
Alzheimer’s disease (Mercy et al., 2008; Perry and Miller, 2013;
Baizabal-Carvallo and Jankovic, 2016). Remarkably, over 6% of
sporadic ALS/FTD cases and over 37% familial ALS/FTD cases
are caused by the expansion of the GGGGCC hexanucleotide
repeat in the first intron of the C9ORF72 gene (Majounie et al.,
2012).
Jin and colleagues pioneered the firstDrosophilamodel of C9-
ALS/FTD by expressing 30 GGGGCC repeats [(GGGGCC)30]
with a reporter in the compound eye, which resulted in severe
retinal degeneration (Xu et al., 2013). When (GGGGCC)30 was
expressed in motor neurons, it resulted in defective locomotor
activity; whereas when it was expressed in the central nervous
system using a pan-neuronal driver, it resulted in lethality (Xu
et al., 2013). One important question to be answered was how
GGGGCC repeats actually cause the disease. The pathogenesis
could be due to: (1) loss-of-function of wild-type C9ORF72
protein, (2) gain-of-function of toxic RNA consisting of the
GGGGCC repeats, and/or (3) gain-of-function of toxic dipeptide
repeat (DPR) proteins generated by RAN translation. Although
the mild phenotypes in a homozygous C9ORF72 mutation case
and the lack of C9ORF72 coding mutations suggest that wild-
type protein loss-of-function is unlikely the primary cause of
C9-ALS/FTD (Fratta et al., 2013; Harms et al., 2013), loss-of-
function of the wild type protein is still a possible mechanism
that contribute to the disease pathogenesis. Since Drosophila
does not have an ortholog of C9ORF72, the fly may not be a
suitable model organism for investigating the haploinsufficiency
aspect of C9ORF72. The fly, however, proved a valuable tool in
determining the gain-of-function toxicity of GGGGCC repeats
in C9-ALS/FTD. In the attempt to differentiate between repeat
RNA and DPR protein toxicity, Isaacs and colleagues generated
stop codon-interrupted RNA-only (RO) repeats of GGGGCC
and compared it with pure GGGGCC repeats which can be RAN-
translated into DPR proteins in Drosophila (Mizielinska et al.,
2014). Isaacs and colleagues found that, the expression of RO
(GGGGCC)36 or pure (GGGGCC)36 results in the same amount
of ribonuclear foci formation. However, the expression of all RO
constructs, including RO (GGGGCC)36, RO (GGGGCC)108, and
even RO (GGGGCC)288, had no detectable effect on the fly eye.
In contrast, both pure (GGGGCC)36 and pure (GGGGCC)103
caused degeneration. These findings suggest that, although both
RNA and DPR proteins may contribute to toxicity, degeneration
was primarily attributable to DPR proteins (Mizielinska et al.,
2014). To further investigate whether DPR protein expression
alone was sufficient to cause degeneration, they generated four
“protein-only” constructs by using alternative codons. When
expressed in the fly eye, only glycine-arginine (GR)36 and
proline-arginine (PR)36 constructs resulted in degeneration,
whereas glycine-alanine (GA)36 and proline-alanine (PA)36 had
no detectable effect. Even at the repeat length of 100, same
results were obtained for the above DPR proteins, indicating
that high arginine-containing DPR protein is the major cause of
neurodegeneration in C9-ALS/FTD (Mizielinska et al., 2014).
To determine the molecular mechanism that underlies DPR
proteins-induced degeneration, Taylor, Gao and colleagues
generated reporter-tagged (GGGGCC)58 flies, and performed
a screen to look for genetic modifiers of GGGGCC-induced
eye degeneration (Freibaum et al., 2015). Eighteen modifier
genes were identified with the majority of them being
transcription/export (TREX) complex proteins and nuclear pore
complex proteins, involving particularly nuclear export of RNA.
Lastly, Taylor, Gao and colleagues predicted that (GGGGCC)58
can produce poly(GA), poly(GR), or poly(GP) DPR proteins
by RAN translation. Consistent with an aforementioned study,
they found that the arginine-containing poly(GR) to be highly
toxic (Freibaum et al., 2015). In summary, the researchers
demonstrated that GGGGCC repeat expansion compromises
nucleocytoplasmic transport, facilitating nuclear retention of
toxic RNAs. Whereas the build-up of toxic poly(GR) DPR
proteins by RAN translation is a major cause of GGGGCC-
induced neurodegeneration. Rothstein and colleagues also
conducted a screen to search for interactors for GGGGCC
RNA, and uncovered RanGAP as a potent suppressor of
neurodegeneration (Zhang et al., 2015). RanGAP is a key
regulator of nucleocytoplasmic transport, supporting that the
nucleocytoplasmic transport mechanisms are involved in the
neurodegeneration in C9-ALS/FTD (Zhang et al., 2015).
In the same year, another screen performed in yeast by
Gitler and colleagues identified effectors of Ran-mediated
nucleocytoplasmic transport and karyopherins as modifiers of
GGGGCC-induced DPR protein toxicity (Jovicic et al., 2015). A
recent study by Van Den Bosch and colleagues also reported the
results of aDrosophila genetic screen, which identified importins,
exportins, Ran-GTP cycle regulators, nuclear pore components
and arginine methylases as potent modifiers of DPR protein
toxicity (Boeynaems et al., 2016). Taking a different approach,
Taylor and colleagues analyzed the interactome of all DPR
proteins in human cells, and found that arginine-containing
DPR proteins (GR and PR) interact with RNA-binding proteins
with low complexity sequence domains (LCDs), such as TDP-
43, FUS, hnRNPA1, hnRNPA2B1, Matrin-3, and Ataxin-2 (Lee
et al., 2016). Using the Drosophila eye, they confirmed that these
proteins are genetic modifiers of DPR protein-induced toxicity.
Remarkably, most of these genetic modifiers encode components
of membrane-less organelles, including the nucleoli, the nuclear
pore complexes and stress granules. The researchers showed that
GR and PR bind to the LCD-containing RNA-binding proteins,
alter their biophysical properties, and lead to impairment of their
assembly, dynamics, and functions (Lee et al., 2016).
A consensus from all these studies was that the DPR
proteins that cause toxicity in C9-ALS/FTD contain arginine.
Arginine is a unique amino acid that has as many as five
potential hydrogen-bond donors that are readily available to
react with biological hydrogen-bond acceptors. In DNA-protein
complexes, arginine residues are the most frequent hydrogen
bond donors to backbone phosphate groups (Luscombe et al.,
2001). Networks of hydrogen bonds can be formed by arginine
residues with phosphate groups of RNA loops as well (Calnan
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et al., 1991). Whereas among the interactions between amino
acids, the arginine-aspartate double hydrogen-bond interaction
is also an extremely stable structure (Mitchell et al., 1992). Each
methylation of an arginine residue removes a potential hydrogen-
bond donor, and changes the shape of the amino acid. Thus,
methylation can reduce the chance of arginine bonding to its
interactors, which in turn increases the chance of an arginine-
containing DPR protein to be degraded. This is supported by
the finding that arginine methylases are potent modifiers of DPR
protein toxicity (Boeynaems et al., 2016).
Arginine-containingDPR proteins have been proven toxic in a
number of studies by various groups. But the question remained
whether the nuclear GGGGCC repeat-containing RNA induces
toxicity. The study above by Isaacs and colleagues did not detect
any significant degeneration when as many as 288 repeats (RO)
were expressed in the fly eye (Mizielinska et al., 2014). Gao and
colleagues further explored this important question, and tested
the effects of aDrosophilamodel expressing aC9ORF72minigene
with 160 GGGGCC repeats (160R; Tran et al., 2015). The 160R
in this model is flanked by human intronic and exonic sequences
of C9ORF72. Intriguingly, even though the spliced intronic 160R
formed abundant nuclear GGGGCC sense RNA foci, they gave
rise to no detectable neurodevelopmental defects. Cells were also
normal in their rRNA biogenesis and mRNA processing (Tran
et al., 2015). When 160R flies were reared at 29◦C instead of
the normal 25◦C, a modest level of toxicity was detected. But
since the higher temperature induced 4-foldsmore DPR proteins,
while the number of RNA foci did not change, it is likely that
this toxicity was due to the increased DPR proteins instead of the
RNA foci (Tran et al., 2015).
Summarizing the above studies, the GGGGCC repeat
expansion in C9-ALS/FTD share much commonalities with
other READs such as the formation of foci, sequestration of
RNA-binding proteins, and induction of nucleolar stress. Yet,
unlike most other READs described here, the RNA transcripts
containing the GGGGCC repeat expansions and the foci in C9-
ALS/FTD do not appear to be the main source of toxicity. Rather,
it is the DPR proteins produced by RAN translation (which can
still arguably be called a type of RNA toxicity) that are the major
determinants of toxicity and degeneration in this disease.
Nevertheless, just when everyone thought GGGGCC repeat-
containing RNA does not give rise to any kind of toxicity,
Bonini and colleagues discovered a new form of GGGGCC RNA
toxicity that may be independent of DPR proteins. In cultured
mice spinal cord neurons, GGGGCC and CAG repeat RNAs
were found to localize to transport granules that travel to distal
neuritic segments (Burguete et al., 2015). Expression of the
GGGGCC repeat-containing RNA gave rise to neuritic branching
defects. Using a Drosophila model, the researchers found that
this branching defects can be enhanced by the upregulation or
suppressed by the downregulation of dfmr1 or orb2 (Burguete
et al., 2015). The researchers speculated that the presence of
GGGGCC repeat RNA in neurites might result in local RAN
translation of toxic DPR proteins. However, they were unable to
detect RAN peptides in their study (Burguete et al., 2015). These
findings demonstrate that GGGGCC expanded repeat RNAs can
cause transport granule dysfunction, which could be a novel RNA
toxicity mechanism independent of DPR proteins, contributing
to the neuronal defects in C9-ALS/FTD.
It is important to note that, hexanucleotide repeats such
as GGGGCC, are capable of forming distinct structures called
DNA and RNA G-quadruplexes (Reddy et al., 2013; Haeusler
et al., 2014). These structures facilitate DNA/RNA hybrids,
impedes transcription and binds to ribonucleoproteins such as
NCL, inducing nucleolar stress (Haeusler et al., 2014). They
also form inclusions and sequester hnRNP H, which impedes
alternative splicing (Conlon et al., 2016). The real impacts of these
G-quadruplex structures on the pathogenesis of C9-ALS/FTD are
only just beginning to be elucidated.
THERAPEUTIC DEVELOPMENT TO
COMBAT RNA TOXICITY IN READS
Much progress has been made in the past decade regarding
potential therapeutic strategies against the RNA toxicity in
READs. The current three main streams of therapeutics are
oligonucleotide-based therapeutics, peptoid-based therapeutics,
and small molecule-based therapeutics. In oligonucleotide-based
therapeutics, antisense-oligos (ASOs) have been demonstrated to
disrupt foci formation and reduce RNA toxicity in both DM1
and C9-ALS/FTD (Mulders et al., 2009; Wheeler et al., 2012;
Donnelly et al., 2013; Lagier-Tourenne et al., 2013; Sareen et al.,
2013; Riboldi et al., 2014; Wojtkowiak-Szlachcic et al., 2015).
Peptoid-based therapeutics have shown some promising results
in mitigating RNA toxicity in DM1 models by reducing the
interaction between CUG repeats and MBNL1 and decreasing
foci formation (Pushechnikov et al., 2009; García-López et al.,
2011; Rzuczek et al., 2013). It has also been reported that a
13-amino-acid peptide can bind to CAG repeats and suppress
nucleolar stress and neurotoxicity in aDrosophilamodel of SCA3
(Zhang et al., 2016). Last but not least, designs in small molecules
designs have achieved much successes in combating DM1 and
C9-ALS/FTD as well. Non-steroidal anti-inflammatory drugs
like ketoprofen, histamine receptor inhibitors like orphenadrine
and sodium/calcium metabolism modifiers like clenbuterol and
spironolactone have been shown in Drosophila models of DM1
to mitigate the effects of CUG toxicity (Garcia-Lopez et al.,
2008). Pentamidine and neomycin B have been shown to disrupt
MBNL1 binding to CUG repeats (Warf et al., 2009). A number
of small molecules, including bisamidinium inhibitors, can target
toxic RNA-protein interactions and alleviate the sequestration of
MBNL1 by repeat expansions (Gareiss et al., 2008; Kumar et al.,
2012; Parkesh et al., 2012; Wong et al., 2014; Luu et al., 2016).
Porphyrins that distorts RNAG-quadruplex structures can ablate
the GGGGCC repeat expansion’s interaction with hnRNPA1 or
ASF/SF2 (Zamiri et al., 2014). There are small molecules that can
even reduce DPR protein production in a model of C9-ALS/FTD
(Su et al., 2014). Histone deacetylase (HDAC) inhibitors like
sodium butyrate and suberoylanilide hydroxamic acid had been
shown to suppress degeneration in a Drosophila model of HD
(Steffan et al., 2001). Although, this suppression may involve
protein toxicity instead of RNA toxicity. Furthermore, in a
Drosophila model of SBMA and a Drosophila model of FXTAS,
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overexpression of the HDACs themselves actually suppressed
the degeneration phenotypes (Pandey et al., 2007; Todd et al.,
2010). Thus, the effects of HDACs inhibitors could be different
for different types of READs.
The newest trend in the designing of small molecules is
driving toward compounds with multiple modes of actions in
combating the pathogenesis of the disease. Zimmerman and
colleagues have reported a type of small molecule can target DM1
pathology by acting as transcription inhibitors, by inhibiting
aberrant protein binding to toxic RNA, and by acting as RNase
mimics to degrade the toxic RNA (Nguyen et al., 2015). Gitler
and colleagues discovered that the transcription elongation factor
Spt4 selectively decreased both sense and antisense GGGGCC
expanded transcripts, and partially rescued retinal degeneration
in the fly eye model of C9-ALS/FTD (Kramer et al., 2016).
Knockdown of SUPT4H1, the human ortholog of Spt4, decreased
sense and antisense RNA foci andDPR protein production in C9-
ALS/FTD patient-derived cells (Kramer et al., 2016). The study
demonstrated Spt4 as a new potential therapeutic target since
the disruption of Spt4 can ameliorate degeneration induced by
different modes of toxicity sources. Animal models such as the
flymodels described in this review are valuable tools in the testing
of novel compounds and therapeutic targets before clinical trials.
They will also continue to serve as important platforms for
the discoveries of unknown mechanisms of diseases that may
facilitate the development of new therapeutic approaches.
CONCLUDING REMARKS
In this review, we highlighted Drosophila as an excellent model
organism for the studying of READs. The studies mentioned
above have revealed comprehensive information regarding the
mechanisms of neurodegeneration in READs, demonstrating the
elegant use of the fly models in pioneering discoveries of RNA
toxicity. Despite the fact that protein toxicity is a major factor
that contributes to the pathogenesis of many READs, we are now
certain that RNA toxicity also plays a major role in inducing
neural and muscle degeneration via a number of possible ways,
including but not limited to the impairment of alternative
splicing, the promotion of bidirectional transcription, the
induction of nucleolar stress and disruption of nucleocytoplasmic
transport, the generation of sRNA from hairpins and dsRNA,
and RAN translation of repeat-containing peptides. Although
the formation of visible ribonuclear foci is still a hallmark of
pathogenesis, more, and more evidence is indicating that the
initial emergence of foci does not equal to immediate detectable
toxicity. The foci do not initiate the disease process per se. In
fact, the formation of foci could possibly be a healthy response
to temporarily sequester the toxic RNA. Although in the long
run, foci may still contribute to the progression of the disease
by sequestering RNA-binding proteins, and gradually lead to
degeneration.
Apart from the traditional advantages in genetics, the recent
advances in CRISPR/Cas9 system and bioinformatics have
become a powerful driving force that will surely aid Drosophila
research to ascend to the next level. For instance, Liu and
colleagues have developed an improved RNA injection-based
CRISPR/Cas9 system that is highly efficient for creating desired
mutagenesis in the Drosophila genome with a mutagenesis
induction rate up to 88% (Bassett et al., 2013). O’Connor-Giles
and colleagues have expanded the system through homology-
directed repair to facilitate complex genome engineering,
enabling the insertion of sizable DNA sequences to create
targeted knock-ins and conditional knockouts (Gratz et al.,
2014). The CRISPR/Cas9 system can also be used for tissue-
specific tagging of endogenous proteins (T-STEP; Koles et al.,
2015). In contrast to the GAL4/UAS overexpression system,
which sometimes may change the localization patterns of
proteins, T-STEP retains the endogenous protein localization
patterns. Furthermore, it achieves tissue-specific labeling,
allowing researcher to dissect tissue-specific functions of the
protein of interest. Next generation sequencing is now widely
available, and the access of disease information is also becoming
more convenient for Drosophila geneticists as well. Online
databases such as FlyBase has even introduced “Human Disease
Model Reports” recently, further facilitating the studies of
human diseases using the fruit fly (Millburn et al., 2016). With
the development of these techniques and databases, we expect
many new and improved fly models of human diseases to emerge
soon.
In conclusion, Drosophila is a useful in vivo model
system that can reveal novel mechanistic insights into human
disorders, providing the foundation for translational research
and therapeutic development. Looking into the future, we
anticipate the tiny fruit fly to continue playing an important
role in gene and drug discoveries in the ongoing battle
between humans and neurodegenerative and neuromuscular
diseases.
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